PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum
Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.
"Corey Cutler, MD, MPH, FRCP(C) & Miguel-Angel Perales, MD - New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics"
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Philip J. Mease, MD, MACR - IL-17 Inhibitors in Nonradiographic Axial Spondyloarthritis: Expert Insight on Clinical Decision-Making in an Expanding Therapeutic Landscape
Go online to PeerView.com/HYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses treatment with IL-17 inhibitors in nonradiographic axial spondyloarthritis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), Discuss the rationale for IL-17 inhibition as a treatment approach to axSpA, Summarize efficacy and safety data related to IL-17 inhibitors for the treatment of nr-axSpA, Apply anti-IL-17 therapy for the treatment of nr-axSpA in accordance with current evidence and individual patient needs.
Robert Dreicer, MD, MS, MACP, FASCO - Making the Right Moves in the Evolving Prostate Cancer Therapeutic Landscape: Expert Guidance on Treatment Sequencing and Selection for Effective Management Across the Disease Continuum
Go online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patient-, tumor-, and treatment-related factors, as well as how to handle patients’ specific needs and preferences. Upon completion of this activity, participants should be better able to: Review recent safety and efficacy data of emerging and available agents across the prostate cancer disease continuum (nmCRPC, mCSPC, mCRPC), including the latest evidence and expert recommendations for selection and sequencing of approved hormonal and chemotherapy options, Outline the latest clinical evidence for appropriate use of novel therapies (eg, PARP inhibitors and immunotherapy) in mCRPC, including monotherapy and combination approaches, Evaluate the latest genetic testing guidelines to better direct treatment decision-making throughout the prostate cancer disease continuum, Develop evidence-based, tailored treatment plans, including the option of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.
Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT
Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.
Ruben A. Mesa, MD, FACP / Jeanne M. Palmer, MD - How to Manage JAK Inhibition in Patients Undergoing HCT: Applying the Latest Clinical Evidence to Improve Patient Outcomes in Myelofibrosis
Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF. Upon completion of this activity, participants should be better able to: Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF, Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF, Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF, Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting.